Biotechnology company Amgen and privately-run French research-based pharmaceutical company Servier have announced the early termination of the waiting period under the Hart–Scott–Rodino Antitrust Improvements Act of 1976 in connection with the cardiovascular product collaboration agreement announced July 8, completing the transaction.
Amgen has obtained commercial rights in the U.S. to Servier's novel oral drug, approved in the E.U. as Procoralan (ivabradine), for chronic heart failure and stable angina in patients with elevated heart rates. Amgen also has received an exclusive option to develop and commercialize Servier's investigational molecule, S38844, for cardiovascular diseases in the U.S. Currently, S38844 is in phase II studies for the treatment of heart failure. Servier has obtained an exclusive option to commercialize omecamtiv mecarbil in Europe. Omecamtiv mecarbil is an activator of cardiac myosin, which currently is being tested for potential applications in the treatment of heart failure in patients with systolic dysfunction.